ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MIST
GNLX (26) RTSN (51) TNXP (25) NTHI (31) ⌘ Pro Terminal →

Milestone Pharmaceuticals Inc. (MIST) — RQD Stock Rating Cockpit

$0.72 -1.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.72

Milestone Pharmaceuticals Inc. (MIST) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $89.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MIST Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MIST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.72 (-1.22% 1D, market cap $89.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MIST ranks #690 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MIST compare to GNLX and RTSN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNLX (Genelux Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $90.5M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $89.1M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MIST?
▼

Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $174.0M in revenue (+47.6% YoY), -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.72 (-0.41%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (4)Whales (7)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE MIST RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MIST)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY MIST SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$0.79-12.7% Next Q
Q2 (-2Q)
38
Grade E$0.69+10.1% Next Q
Q3 (-1Q)
36
Grade E$0.76-5.3% Next Q
Current
33
Grade E$0.72-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MIST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MIST currently carries a cautious 33/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.76) forces dealer call-delta covering toward $3.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MIST• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MIST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
43.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE4% OF RANGE
L: $1$0.72H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on MIST

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (32)

12/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like MIST
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MIST)

  • ✓Walkthrough of MIST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MIST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.70%⚡ TESTING RESISTANCE
2026-11-04O $0.73H $0.73L $0.72C $0.72VOL 748.8K
RES: $0.80SUP: $0.59SMA50: $0.87SMA200: $1.35
$2.12$1.71$1.31$0.91$0.50RES $0.80SUP $0.59$0.722026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MIST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MIST Butterfly Map → + Track MIST →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +47.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MIST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MIST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MIST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MIST)

Health Care Rank #690 of 1015 ⚔️ GNLX vs MIST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MIST vs. GNLX, RTSN, TNXP, NTHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Milestone Pharmaceuticals Inc. (MIST) ranks #690 by composite RQD confidence (33/100, grade E) and #665 by equity capitalization ($89.8M). Within this direct 5-issuer industry benchmark cohort, MIST leads on earnings valuation at N/A trailing P/E, while MIST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RTSN currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with MIST at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MIST ACTIVE
Milestone Pharmaceuticals Inc.
E 33/100 — — -35.0% -1.22% $89.8M Benchmark Subject
GNLX
Genelux Corporation
E 26/100 — — -35.0% -3.85% $90.5M /gnlx-vs-mist →
RTSN
Retension Pharmaceuticals Inc.
D 51/100 — — — -0.53% $89.1M /rtsn-vs-mist →
TNXP
Tonix Pharmaceuticals Holding Corp.
E 25/100 — 49.3% -35.0% +0.98% $88.3M /tnxp-vs-mist →
NTHI
NeOnc Technologies Holdings Inc.
E 31/100 — — -35.0% -5.83% $91.4M /nthi-vs-mist →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001408443 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Pharmaceuticals Inc. (MIST) reported GAAP revenue of $174.0M (+47.6% vs. FY2024 revenue of $117.9M , and +1.7% cumulative change since FY2023) , GAAP net income of -$63.1K, operating cash flow of -$49.0M, and free cash flow of -$49.3M (-70.8% YoY). On the balance sheet, MIST closed FY2025 with $113.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $174.0M -$63.1K -$49.0M -$49.3M $113.6M —
FY2024 (FY) 2024-12-31 $117.9M -$41.5K -$28.8M -$28.9M $75.5M —
FY2023 (FY) 2023-12-31 $171.1M -$59.7K -$46.4M -$46.4M — —

3. MIST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MIST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.72 (-1.22% 1D, market cap $89.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, MIST ranks #690 in composite RQD confidence.

How does MIST compare to GNLX and RTSN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNLX (Genelux Corporation) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $90.5M) and RTSN (Retension Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $89.1M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MIST?

Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $174.0M in revenue (+47.6% YoY), -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MIST trading relative to its 50-day, 200-day, and 52-week technical levels?

MIST last traded at $0.72 (-1.22% on volume of 748,839 shares), positioning the stock -17.24% below its 50-day simple moving average ($0.87) and -46.67% below its 200-day simple moving average ($1.35). Across its 52-week range of $0.63 to $3.06, MIST sits at the 3.7% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

Direct Sub-Reports: MIST RQD Cockpit MIST 12M Forecast MIST Earnings & Move MIST Dividends & DRIP MIST Insiders & 13F MIST Whale Options MIST Profit Sankey MIST News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

MIST — Milestone Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Milestone Pharmaceuticals Inc. (MIST) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.72 (-1.22% 1D, market capitalization $89.8M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Milestone Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Reported revenue is — in each of the three periods shown, indicating no revenue recognition in the reported data. Market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Milestone Pharmaceuticals Inc. (MIST) reported $174.0M in annual revenue (up from $117.9M in FY2024, +47.6% YoY) and -$63.1K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($171.1M revenue, -$59.7K net income) through FY2025, MIST scaled operating cash flow to -$49.0M and free cash flow to -$49.3M, backed by $113.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.63 – $3.06 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MIST carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MIST sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $174.0M and free cash flow of -$49.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MIST's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MIST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Milestone Pharmaceuticals Inc. (MIST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MIST Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MIST Bull vs. Bear Conversation Board — What's Your Call at $0.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MIST 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MIST:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.93 (+27.4%)
📌 Pinned Debate

Institutional accumulation and options positioning score 15 of 20, and a GREEN clinical enrollment item signals some pipeline progress.

Institutional accumulation and options positioning score 15 of 20, and a GREEN clinical enrollment item signals some pipeline progress.. When you look under the hood at MIST, Fundamental Cash Engine is 4/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $3.06. My 12M target is $0.93.

CapAlloc_Nerd 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.57 (-21.9%)
Spot @ $0.73

ROIC of -35%, FCF of -$49.3M in FY 2025, and a Piotroski F-Score of 1/9 combine with active Nasdaq listing-compliance issues.

Here is the bear case nobody on the bull side wants to address on MIST: ROIC of -35%, FCF of -$49.3M in FY 2025, and a Piotroski F-Score of 1/9 combine with active Nasdaq listing-compliance issues.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE